Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The issuance of H-share convertible bonds is a strategic move to further international capital layout and support the implementation of three core strategies: "Great Health and Wellness," "Artificial Intelligence+," and "Internationalization" [6][7] - The net proceeds from the bond issuance will be used to support the insurance main business, the three core strategies, and to supplement working capital [7] - The company aims to enhance its cross-border service capabilities and global asset allocation through this internationalization strategy, leveraging Hong Kong as a key hub [7] Summary by Relevant Sections Company Overview - Total share capital is 9,620.34 million shares, with a market price of CNY 38.14 and a market capitalization of CNY 366,919.82 million [4][3] Financial Performance - The forecasted net profit attributable to the parent company for 2025 is CNY 39,734 million, reflecting a year-on-year decrease of 11.6% [5] - The earnings per share (EPS) for 2025 is projected to be CNY 4.13, with a net asset return rate of 13.0% [5][10] Convertible Bond Details - The convertible bond issuance is sized at HKD 15.556 billion, maturing on September 18, 2030, with a conversion price of HKD 39.04, representing a premium of approximately 21.2% over the closing price on the issuance date [7][8] - If fully converted, the bonds would result in approximately 398 million new shares, accounting for about 4.14% of the existing share capital [7][8] Capital Adequacy - As of the end of the first half of 2025, the comprehensive solvency adequacy ratio is 264%, and the core solvency adequacy ratio is 190% [7][8] - The issuance of convertible bonds is expected to enhance the solvency ratios by approximately 7.02 percentage points post-conversion [7][8] Profit Forecast - The projected net profit for 2026 and 2027 is CNY 42,084 million and CNY 44,257 million, with year-on-year growth rates of 5.9% and 5.2% respectively [10]

Report Industry Investment Rating - The report does not explicitly state the industry investment rating. Report's Core View - In the low - interest and high - volatility market environment, dividend investment is popular. The China Securities Chengtong Central Enterprise Dividend Index has significant advantages, and the Rongtong China Securities Chengtong Central Enterprise Dividend ETF provides an efficient tool for investors to invest in high - quality central enterprise dividend assets [2][4]. Summary According to Relevant Catalogs 1. Dividend Investment - A Long - Term Winning Strategy across A - Share Style Rotations 1.1 Long - term Allocation Value of Dividend Assets - Dividend investment focuses on stable cash - flow and profit growth of companies. In the context of China's low - interest environment and style rotations, dividend assets have more prominent allocation advantages compared to bonds. As of 2025, the dividend yield of the CSI Dividend Index is over 4.3%, higher than the 10 - year Treasury bond yield [7]. 1.2 "Offensive and Defensive" Attributes of Dividend Investment - Dividend investment offers both long - term allocation value from dividends and relatively stable capital gains. It shows strong anti - decline and defensive capabilities in bear markets and can also benefit from economic upswings. From 2005 - 2024, high - dividend indices led the market in 9 years, and from 2015 to the present, the CSI Dividend Index has outperformed the Shanghai Composite Index [9]. 1.3 Allocation Value of the "Dividend + Fixed - Income" Portfolio - The "dividend + fixed - income" portfolio is a cost - effective strategy in a low - interest environment. It can enhance the overall return and reduce volatility. The correlation between the CSI Dividend Index and the 10 - year Treasury bond rate from 2015 to now is - 0.5 [13]. 2. How to Choose a Dividend Index 2.1 Comparison of Dividend Index Compilation Methods - Dividend index compilation mainly involves sample selection and index calculation. Traditional dividend indices use historical dividend yields, which have limitations. The China Securities Chengtong Central Enterprise Dividend Index is the first in the A - share market to use the expected dividend yield for stock selection and weighting, considering both dividend willingness and ability [16]. 2.2 Analysis of the Return Characteristics of Different Dividend Indices - Different dividend indices have different risk - return characteristics. From 2017 - 2025, the China Securities Chengtong Central Enterprise Dividend Index has high returns, a high Sharpe ratio, and low drawdowns. It has outperformed indices like the CSI 300, CSI Dividend Index, and CSI Central Enterprise Dividend Index by about 20 percentage points in cumulative returns and nearly 2 percentage points in annualized returns [19][28]. 3. Rongtong China Securities Chengtong Central Enterprise Dividend ETF: A New Choice for Dividend Investment 3.1 Policy - Driven Valuation Repair of Central Enterprise Dividends - Central enterprises are important pillars of the national economy with high stability. Their valuations are currently low but have great potential for repair. Policies such as the improvement of the central enterprise assessment system and market - value management policies are driving the valuation increase [31][33][35]. 3.2 Advantages of the China Securities Chengtong Central Enterprise Dividend Index - The index has four features: it uses the expected dividend yield, focuses on mid - large - cap high - dividend cyclical stocks, does not include bank stocks, and has high dividends and low valuations. As of August 2025, its dividend yield is 4.38%, higher than the central enterprise and A - share averages [36][38][40]. 3.3 High Returns, High Sharpe Ratio, and Low Drawdowns of the Chengtong Central Enterprise Dividend Index - Since 2017, the index has achieved a cumulative return of 56.02% and an annualized return of 5.41%. Considering dividends, the cumulative return is 113.16%. It has better risk - return characteristics compared to other indices [43]. 3.4 Investment Strategy and Applicable Scenarios of the Rongtong China Securities Chengtong Central Enterprise Dividend ETF - The fund is a fully passive index fund using the full - replication method. It is suitable for long - term allocation by pension funds, insurance funds, and conservative investors. It also offers tactical allocation opportunities and can be used as a defensive asset in a volatile market. As of August 2025, its management and custody fees are lower than most similar products [45][46][47].

Investment Rating - The report maintains an "Accumulate" rating for the industry [5] Core Insights - The pharmaceutical and biotechnology industry is expected to experience a turning point and growth resonance, with a focus on the resilience of the raw material drug sector amidst various macro and micro factors [7][10] - The industry is characterized by a significant number of listed companies, totaling 494, with a total market value of 77,409.20 billion and a circulating market value of 70,487.38 billion [2] Summary by Sections Industry Overview - The report analyzes 47 representative raw material drug companies, indicating that despite pressures on revenue, the profit margins are showing improvement, reflecting the industry's resilience [10] - The average revenue growth rate for the 47 companies in the first half of 2025 was -5.38%, while the average growth rate of non-recurring net profit was 14.43% [10][12] Financial Performance - Key companies such as Xinhecheng, Aoruite, Tianyu Co., Meinuohua, and others have achieved over 10% growth in revenue and non-recurring net profit [10] - The report highlights that the non-recurring net profit of Xinhecheng increased significantly by 70.50% year-on-year in the first half of 2025 [10] Market Trends - The report notes that the prices of major raw materials are currently at low levels, particularly for certain categories like sartans and heparins, with expectations for gradual price recovery as excess capacity is cleared [7][10] - The investment strategy for the second half of the year focuses on identifying companies that are at a turning point in their existing business while also exploring new growth opportunities [7][10] Company Recommendations - The report suggests focusing on companies such as Tianyu Co., Sitaly, Tonghe Pharmaceutical, Meinuohua, Xianju Pharmaceutical, and Puluo Pharmaceutical for potential investment opportunities [7][10]

Investment Rating - The report maintains an "Overweight" rating for the insurance sector [2] Core Insights - The P/CE-ROCE valuation system has been updated based on the 1H25 financial results of listed insurance companies, highlighting the resilience of group insurance companies amid fluctuating net asset values and differing liability assessment curves [5][27] - The report emphasizes the importance of the new valuation framework, which integrates comprehensive equity (CE) and comprehensive equity return rate (ROCE) to better reflect the true value of insurance companies under new accounting standards [5][42] Summary by Sections 1. P/CE-ROCE Valuation System Overview - The P/CE-ROCE valuation system was introduced to address the limitations of the previous P/EV-ROEV framework, focusing on comprehensive equity (CE) as a more accurate measure of insurance company value [5][11] - The system calculates CE as the sum of net assets (NA) and net contract service margin (CSM), providing a clearer picture of profitability and asset-liability matching [5][11] 2. Industry Performance Analysis - In 1H25, the comprehensive equity (CE) growth varied among listed insurance companies, with China Life Insurance leading at 7.0% growth, while Sunshine Insurance and Xinhua Insurance experienced declines of -4.2% and -6.7%, respectively [5][31] - The overall industry saw a 1.4% increase in CE, driven primarily by differences in net asset growth rates among companies [5][31] 3. ROCE Calculation Results - The non-annualized ROCE for listed insurance companies in 1H25 showed significant variation, with China Life Insurance achieving the highest ROCE at 9.2%, while Sunshine Insurance and Xinhua Insurance reported negative ROCE values [5][39] - The report notes a 13.0% year-on-year decline in overall comprehensive income (CI) for the sector, influenced by market interest rate changes and negative contributions from other comprehensive income (OCI) [5][37] 4. Valuation System Fit - The P/CE-ROCE system demonstrated a better fit for H-share listed insurance companies compared to A-share companies, indicating a positive correlation between ROCE and P/CE valuations [5][40] - The report concludes that the new CE valuation system provides a more prudent and comprehensive assessment of insurance companies' value, avoiding the over-reliance on long-term economic assumptions [5][42]

Investment Rating - The report maintains a rating of "Buy" for key companies in the CRO and CDMO sectors, including WuXi AppTec, WuXi Biologics, and others [4][12]. Core Insights - The report indicates that the current industry cycle is expected to continue, driven by improved global liquidity, recovering overseas demand, and technological breakthroughs in areas such as XDC, peptides, and oligonucleotides [6][19]. - In the first half of 2025, the CRO and CDMO sectors showed significant revenue growth, with a 10.4% increase in revenue and a 73.2% increase in net profit attributable to shareholders [6][30]. - The report highlights a divergence in performance between CDMO and CRO, with CDMO experiencing rapid growth while CRO faces slight pressure [6][23]. Summary by Sections Revenue and Profit - In the first half of 2025, the CRO and CDMO sectors achieved a total revenue of 709.1 billion yuan, reflecting a 10.4% year-on-year increase [21]. - The net profit attributable to shareholders reached 151.4 billion yuan, up 73.2%, while the adjusted Non-IFRS net profit was approximately 165.8 billion yuan, marking an 84.8% increase [30][35]. Key Indicators - Demand recovery is evident, with significant increases in orders for major companies such as WuXi AppTec, which reported a 37.2% year-on-year increase in orders [7][37]. - The report notes that the CDMO sector's revenue reached approximately 320.8 billion yuan, a 40.8% increase, while CRO revenue was about 235.9 billion yuan, down 3.5% [23][30]. Focus Companies - The report identifies 30 key companies in the CRO and CDMO sectors, including WuXi AppTec, WuXi Biologics, and others, which are expected to benefit from ongoing industry trends [12][19]. - Specific companies like WuXi Biologics and WuXi AppTec are highlighted for their strong order backlogs and growth potential [38]. Investment Recommendations - The report suggests focusing on CDMO companies due to their expected growth driven by technological advancements and increasing demand for commercialized products [8][19]. - For CRO companies, the report anticipates a gradual recovery as the investment environment improves and orders stabilize [8][19].

Group 1 - The report emphasizes that a single high dividend yield factor is insufficient to navigate through a declining interest rate cycle, suggesting enhancements based on interest rate trends [2][6] - It highlights that while long-term interest rates are expected to decline slowly, short-term rates are entering a plateau phase, necessitating a dual focus on "stable earnings" and "high growth" for future high dividend strategies [2][6] - The report indicates that the correlation between interest rate declines and stock market performance is weak, particularly in the context of deteriorating fundamentals, which can offset the benefits of lower discount rates [2][6] Group 2 - The report outlines the direct effects of low interest rates on stock pricing through the discount rate mechanism, noting that lower rates can enhance the present value of future cash flows, particularly for stocks with high long-term cash flow [9][11] - It discusses the indirect effects of low interest rates on corporate earnings and growth expectations, stating that while lower rates can improve balance sheets, they often coincide with pressure on earnings, limiting their positive impact [11][15] - The report provides historical context, comparing the experiences of the US and Japan during low interest rate periods, noting that stock performance often diverges from economic indicators during such times [18][24] Group 3 - The report critiques the traditional view of high dividend strategies, arguing that they do not consistently maintain high returns during low interest rate environments, as evidenced by the performance of high dividend indices in the US and Japan [29][40] - It suggests that high dividend strategies should be enhanced by focusing on factors such as stable earnings, high growth, strong cash flow, and low volatility, adapting to different interest rate phases [48][60] - The report presents a model for constructing high dividend indices that incorporates a broader range of factors beyond just dividend yield, aiming for a more comprehensive investment strategy [54][57]

Investment Rating - The report maintains an "Increase" rating for the company, indicating a positive outlook for the stock's performance over the next 6 to 12 months [2][6]. Core Insights - The company has experienced significant revenue and profit growth, with a 33.5% year-on-year increase in revenue to 180 million yuan in the first half of 2025, and a 117.7% increase in net profit to 2.168 million yuan [5]. - The company is advancing its IP and AI ecosystem, with successful product launches and a focus on children's content, which has led to a strong market position [5][6]. - The company's gross margin has improved, reaching 42.5% in the first half of 2025, driven by the success of popular children's books [5]. - The company is actively developing its original IP "Lily Lan's Little Bug," which has sold over 3.1 million copies, and is expanding into animation and merchandise [5]. - Collaborations with technology partners like Alibaba Cloud are enhancing the company's AI capabilities in children's education [5]. Financial Performance Summary - Revenue projections for 2025-2027 are 367 million yuan, 497 million yuan, and 658 million yuan, representing year-on-year growth rates of 37.9%, 35.7%, and 32.4% respectively [2][6]. - Net profit forecasts for the same period are 14 million yuan, 39 million yuan, and 60 million yuan, with growth rates of 131.2%, 184.5%, and 52.3% respectively [2][6]. - The company's earnings per share (EPS) is expected to improve from -0.53 yuan in 2024 to 0.71 yuan in 2027 [2][6].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][6] Core Views - The company is experiencing growth driven by smart home solutions and cloud services, with AI enhancing high-margin business profitability [1] - The company has successfully entered the smart home market, leveraging its AI visual technology capabilities inherited from its parent company, Hikvision [3] - The dual-driven model of smart home hardware and cloud services positions the company for potential growth as an ecosystem-level enterprise [3] Financial Performance Summary - For the first half of 2025, the company achieved revenue of 2.827 billion yuan, a year-on-year increase of 9.45%, and a net profit of 302 million yuan, up 7.38% year-on-year [3] - The smart home segment led revenue growth, with smart home cameras generating 1.548 billion yuan (54.75% of total revenue) and a gross margin of 39.07% [3] - The cloud service segment reported revenue of 555 million yuan, accounting for 19.63% of total revenue, with a gross margin of 72.09% [3] Revenue and Profit Forecast - The company forecasts revenues of 5.442 billion yuan for 2024, 6.181 billion yuan for 2025, and 7.065 billion yuan for 2026, with a compound annual growth rate of 14% [1] - Net profit is projected to be 615 million yuan in 2025 and 754 million yuan in 2026, reflecting a growth rate of 22% [1][3] Valuation Metrics - The price-to-earnings (P/E) ratio is expected to decrease from 52.6 in 2024 to 43.1 in 2025, indicating improving valuation [1] - The price-to-book (P/B) ratio is projected to decline from 4.8 in 2024 to 4.5 in 2025 [1] Strategic Initiatives - The company is enhancing its product offerings with the launch of the self-developed AI facial recognition video lock, which integrates personalized AI capabilities [3] - The company is focusing on channel construction and improving its retail matrix both domestically and internationally [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The company reported a revenue of 14.644 billion yuan for the first half of 2025, representing a year-on-year growth of 25.25%. The net profit attributable to shareholders was 1.223 billion yuan, with a year-on-year increase of 45.82%. The annualized sales from new project orders exceeded 18 billion yuan [4] - The company is accelerating its international layout and strategically entering new sectors, particularly in smart cockpit and smart driving technologies. The sales revenue from smart cockpits reached 9.459 billion yuan in the first half of 2025, growing by 18.76% year-on-year. The company has secured new project orders from major clients such as Li Auto, Xiaomi, and Geely [5] - The company is investing in AI technology and exploring new fields such as smart transportation, unmanned delivery, and robotics, aiming to create a new growth curve for sustainable development [5] Financial Forecasts and Valuation - The company is expected to achieve net profits of 2.802 billion yuan, 3.540 billion yuan, and 4.472 billion yuan for the years 2025, 2026, and 2027 respectively. The previous estimates for 2025 and 2026 were 2.817 billion yuan and 3.617 billion yuan [5] - The projected revenue for the company is 27.618 billion yuan for 2024, 34.599 billion yuan for 2025, 42.559 billion yuan for 2026, and 51.289 billion yuan for 2027, with corresponding growth rates of 26%, 25%, 23%, and 21% [3][7] - The company’s P/E ratio is projected to decrease from 34.3 in 2024 to 15.4 in 2027, indicating an improving valuation as earnings grow [3]

中 泰 证 券 研 究 所 专 业 ｜ 领 先 ｜ 深 度 ｜ 诚 信 ｜ 证 券 研 究 报 告 ｜ 无人物流行业兴起，无人叉车企业或充分受益 —低速无人行业系列研究报告之二 2 0 2 5 . 9 . 9 Email：wangke03@zts.com.cn Email：kouhj@zts.com.cn 分析师：王可 分析师：寇鸿基 执业证书编号：S0740519080001 执业证书编号：S0740525060005 多元因素共振：无人物流开启 大规模商业化应用 1 目录 2 无人车规模化落地第一站，无 人物流车快速增长 3 仓储端：智能叉车进阶，技术融 合与场景拓展双轮驱动 4 对应标的：无人叉车方兴，上市 公司进一步打开增长极 3 核心观点 p 无人物流行业迈向全面商业化阶段：历经2010-2016的探索时期、2016-2023的商业化突破阶段、2024年以来， 无人驾驶物流车正在向全面商业化迈进。无人配送车的应用场景从特定区域扩展到完全开放道路，头部科技公 司/物流公司开始大规模量产，头部企业车队/产能规模直指万台级别。 p 关键部件成本降至商用阈值，驱动大规模订单落地。激光雷达、域控制器作为单一价 ...